RESEARCH MONOGRAPH · KDC-MN-319

Amantadine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

76/100

Old anti-flu drug with a second life in Parkinson's and TBI, and the mechanism is still partly unclear

Amantadine has had three lives. It started in the 60s as an anti-influenza drug (now obsolete because of resistance), then became a Parkinson's adjunct for dyskinesia, and more recently picked up some interest in traumatic brain injury recovery and ADHD. Thats a weird trajectory for a small adamantane.

The mechanism story is honestly still partly unclear. It's typically described as a weak non-competitive NMDA antagonist with additional dopamine-releasing properties, but the affinity at NMDA is modest, the dopamine-releasing data is mostly inferential, and which effect dominates in vivo at clinically relevant exposures is still debated. Blanpied and Bormann had nice channel-block kinetics work showing it sits in the open NMDA channel similar to memantine but with faster off-rate, which might explain why it's clinically tolerable at doses where most NMDA antagonists would cause real psychotomimetic effects.

The Giacino trial in disorders of consciousness after severe TBI is honestly the most interesting clinical signal in its modern resume. NEJM 2012, placebo-controlled, showed real recovery acceleration in vegetative and minimally conscious patients. That's a hard study to do and a hard endpoint to move, and they did. The mechanism, presumably some combination of NMDA modulation and catecholamine release, is plausible but not pinned down.

For Parkinson's dyskinesia (LID) it's the standard adjunct and works pretty consistently. Mechanism there is more cleanly NMDA-mediated, the Verhagen Metman trials are solid.

Pharmacology: oral bioavailability ~90%, renally cleared (which matters), half-life ~15 hours, predictable. Hydrochloride salt is standard, sulfate also available. Sourcing is rock solid, USP grade is widely available cheap, generic ubiquity helps.

What we like: tolerable, well-characterized PK, plausible polypharmacology that maps onto real clinical effects. For TBI-recovery modeling work or dyskinesia research it's a reliable tool. Easy to use in vivo.

What we dont like: the mechanism ambiguity makes mechanistic interpretation of behavioral effects genuinely hard. And the CNS side-effect profile (livedo reticularis, hallucinations, especially in older models) is well-documented.

Established compound with a more interesting modern resume than people give it credit for.

Evidence: 82
Mechanism: 60
Reliability: 75
Safety: 75
Sourcing: 90
Value: 85
Signal: 70
Staying power: 72

Plain-language summary Intrigue 60 / 100

Amantadine started life in 1968 as an oral antiviral for influenza A and was later discovered to help Parkinson disease patients, an entirely accidental finding that led to its current main role. It works through several mechanisms at once: weak NMDA glutamate receptor blockade (similar to memantine), dopamine release, and dopamine reuptake inhibition. Today it is most useful for the involuntary movements (dyskinesias) that develop after years of L-DOPA therapy, and for cognitive recovery after traumatic brain injury where it has the strongest evidence base of any drug. The flu indication has largely been abandoned because of widespread viral resistance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Adamantane NMDA antagonist + dopamine releaser

An adamantane derivative with NMDA receptor antagonism and dopamine release activity; used in Parkinson disease dyskinesia and (historically) influenza A.

Abstract

Amantadine (1-aminoadamantane; CAS 768-94-5; molecular formula C10H17N; molecular weight 151.25) is a tricyclic amine adamantane derivative developed at DuPont in 1959 and approved by the FDA in 1968 originally as an influenza A antiviral. Mechanism is multifactorial: weak NMDA receptor antagonism (Ki approximately 50 microM, similar to memantine), dopamine release and reuptake inhibition, and (the original mechanism) inhibition of the M2 ion channel in influenza A virus. Influenza A resistance to amantadine became near-universal by 2008, eliminating the antiviral utility. Pharmacological repurposing for Parkinson disease (modest motor benefit; the principal modern use is in levodopa-induced dyskinesia, where the NMDA antagonism reduces involuntary movements) and traumatic brain injury (cognitive recovery, accelerated emergence from minimally conscious state). Plasma half-life is approximately 17 hours; renal excretion is the principal clearance pathway. Used as a reference NMDA antagonist and dopaminergic enhancer.

Mechanism of action

Weak NMDA receptor antagonism (similar to memantine); dopamine release and reuptake inhibition. Multi-target activity in Parkinson dyskinesia and TBI cognitive recovery.

Reported research dose ranges

Clinical 100 to 400 mg in the published literature.

References

Moskovitz BM, et al. Amantadine therapy for Parkinson's disease. Neurology 1978.
Giacino JT, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 2012.
Kornhuber J, et al. Memantine pharmacological action: relevance for amantadine. Neuropharmacology 1991.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-319

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Amantadine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs